home / stock / evok / evok news

EVOK News and Press, Evoke Pharma Inc. From 01/30/23

Stock Information
Company Name: Evoke Pharma Inc.
Stock Symbol: EVOK
Market: NASDAQ
Website: evokepharma.com
Menu
EVOK EVOK Quote EVOK Short EVOK News EVOK Articles EVOK Message Board
Get EVOK Alerts

News, Short Squeeze, Breakout and More Instantly...
EVOK - Evoke stock rises on filing of dismissal in nasal spray Gimoti's patent infringement case

Evoke Pharma ( NASDAQ: EVOK ) stock rose ~4% on Monday after the company said that a joint stipulation of dismissal was filed in the Gimoti's patent infringement case in the U.S. District Court for the District of New Jersey. The filing of the stipulation arises fro...
EVOK - Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that a joint stipula...

EVOK - Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its abstract entitle...

EVOK - Evoke Pharma receives patent for Gimoti to treat moderate to severe gastroparesis

Evoke Pharma ( NASDAQ: EVOK ) is trading 7.1% higher after it received U.S. patent for Treatment of moderate and severe gastroparesis for Gimoti. This patent expires in 2038 and covers the methods for treating moderate-to-severe gastroparesis with metoclopramide via an in...
EVOK - USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that the United Stat...

EVOK - Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and Tr...

EVOK - Evoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call Transcript

Evoke Pharma, Inc. (EVOK) Q3 2022 Results Earnings Conference Call November 10, 2022, 04:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations, DKB Partners David Gonyer - President and Chief Executive Officer Chris Quesenberry - Chief Commerci...
EVOK - Evoke Pharma GAAP EPS of -$0.60 beats by $0.06, revenue of $0.83M beats by $0.26M

Evoke Pharma press release ( NASDAQ: EVOK ): Q3 GAAP EPS of -$0.60 beats by $0.06 . Revenue of $0.83M (-10.8% Y/Y) beats by $0.26M . 80% increase in GIMOTI ® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compare...

EVOK - Evoke Pharma Reports Record Third Quarter 2022 Financial Results

80% increase in GIMOTI ® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compared to Q2 13% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a sp...

EVOK - Evoke Pharma to Report Third Quarter Results on November 9, 2022

SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2...
Previous 10 Next 10